Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Indonesia custom product OEM/ODM services

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Graphene insole OEM factory China

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Graphene sheet OEM supplier factory Taiwan

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Arch support insole OEM factory from Taiwan

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Customized sports insole ODM Indonesia

Mandarinfish (Synchiropus splendidus) is a small, brightly colored member of the dragonet family. Machine learning enables largest study to date on aesthetic preferences and fish ecology. What makes a fish beautiful to humans? Is it colorful, symmetrical, and distinctive? Perhaps you don’t know the features, but you just “know it when you see it.” That works in this study, where people rated the attractiveness of fish in images, and a machine learning (a type of artificial intelligence) neural network was able to learn what types of fish people found more aesthetically pleasing. It turns out that people like fish that are bright and colorful, with rounder bodies. But what is the relationship between people’s perception of beauty and animals’ conservation needs? According to a machine-learning study by Nicolas Mouquet at the University of Montpellier, France, and colleagues, which will be published today (June 7th, 2022) in the open-access journal PLOS Biology, the reef fishes that people find most beautiful tend to be the lowest priority for conservation support. Public Perception vs. Conservation Priorities The researchers asked 13,000 members of the public to rate the aesthetic attractiveness of 481 photographs of ray-finned reef fishes in an online survey and used this data to train a convolutional neural network. They then used the trained neural network to generate predictions for additional 4,400 photographs featuring 2,417 of the most encountered reef fish species. The mandarinfish (Synchiropus splendidus) is among the reef fish species with the highest aesthetic values. Credit: Rick D. Stuart Smith (CC-BY 4.0) Combining the public’s ratings with the neural network’s predictions, they found that bright, colorful fish species with rounder bodies tended to be rated as the most beautiful. However, the species that were ranked as more attractive tended to be less distinctive in terms of their ecological traits and evolutionary history. Furthermore, species listed on the IUCN Red List as “Threatened” or whose conservation status has not yet been evaluated had lower aesthetic value on average than species categorized as “Least Concern.” Unattractive species were also of greater commercial interest, whereas aesthetic value was not correlated with a species’ importance for subsistence fisheries. Mismatched Conservation Efforts and Ecological Value Our innate preferences for shape and color are probably a consequence of the way the human brain processes colors and patterns, the authors say, but mismatches between aesthetic value, ecological function, and extinction vulnerability may mean that the species most in need of public support are the least likely to receive it. The ecological and evolutionary distinctiveness of unattractive fishes makes them important for the functioning of the whole reef, and their loss could have a disproportionate impact on these high-biodiversity ecosystems. Mandarinfish are popular choices for saltwater aquariums. Mouquet adds, “Our study provides, for the first time, the aesthetic value of 2,417 reef fish species. We found that less beautiful fishes are the most ecologically and evolutionary distinct species and those recognized as threatened. Our study highlights likely important mismatches between potential public support for conservation and the species most in need of this support.” Reference: “The aesthetic value of reef fishes is globally mismatched to their conservation priorities” by Juliette Langlois, François Guilhaumon, Florian Baletaud, Nicolas Casajus, Cédric De Almeida Braga, Valentine Fleuré, Michel Kulbicki, Nicolas Loiseau, David Mouillot, Julien P. Renoult, Aliénor Stahl, Rick D. Stuart Smith, Anne-Sophie Tribot and Nicolas Mouquet, 7 June 2022, PLoS Biology. DOI: 10.1371/journal.pbio.3001640 Funding: This research was partially funded through the 2017–2018 Belmont Forum and BiodivERsA REEF-FUTURES project under the BiodivScen ERA-Net COFUND program with the French National Research Agency (DM and NM). This project received additional funding from the LabEx CeMEB and the program PEPS CNRS (NM). RLS data management is supported by Australia’s Integrated Marine Observing System enabled by the National Collaborative Research Infrastructure Strategy (RSS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Researchers at the Broad Institute have improved gene-editing to efficiently insert entire genes into human cells, offering potential for single-gene therapies for diseases like cystic fibrosis. This method combines prime editing with new enzymes to enhance editing efficiency, potentially revolutionizing gene therapy. The gene-editing technique employs prime editors along with advanced enzymes known as recombinases. This method has the potential to lead to universal gene therapies that are effective for conditions like cystic fibrosis. Researchers at the Broad Institute of MIT and Harvard have enhanced a gene-editing technology that can now efficiently insert or replace entire genes in human cell genomes, potentially making it suitable for therapeutic uses. The advance, from the lab of Broad core institute member David Liu, could one day help researchers develop a single gene therapy for diseases such as cystic fibrosis that are caused by one of hundreds or thousands of different mutations in a gene. Using this new approach, they would insert a healthy copy of the gene at its native location in the genome, rather than having to create a different gene therapy to correct each mutation using other gene-editing approaches that make smaller edits. The new method uses a combination of prime editing, which can directly make a wide range of edits up to about 100 or 200 base pairs, and newly developed recombinase enzymes that efficiently insert large pieces of DNA thousands of base pairs in length at specific sites in the genome. This system, called eePASSIGE, can make gene-sized edits several times more efficiently than other similar methods, and is reported in Nature Biomedical Engineering. “To our knowledge, this is one of the first examples of programmable targeted gene integration in mammalian cells that satisfies the main criteria for potential therapeutic relevance,” said Liu, who is senior author of the study, the Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare at the Broad, a professor at Harvard University and a Howard Hughes Medical Institute investigator. “At these efficiencies, we expect that many if not most loss-of-function genetic diseases could be ameliorated or rescued, if the efficiency we observe in cultured human cells can be translated into a clinical setting.” Graduate student Smriti Pandey and postdoctoral researcher Daniel Gao, both in Liu’s group, were co-first authors on the study, which was also a collaboration with Mark Osborn’s group at the University of Minnesota and Elliot Chaikof’s group at the Beth Israel Deaconess Medical Center. “This system offers promising opportunities for cell therapies where it can be used to precisely insert genes into cells outside of the body before administering them to patients to treat disease, among other applications,” Pandey said. “It’s exciting to see the high efficiency and versatility of eePASSIGE, which could enable a new category of genomic medicines,” added Gao. “We also hope that it will be a tool that scientists from across the research community can use to study basic biological questions.” Prime improvements Many scientists have used prime editing to efficiently install changes to DNA that are up to dozens of base pairs in length, sufficient to correct the vast majority of known pathogenic mutations. But introducing entire healthy genes, often thousands of base pairs long, in their native location in the genome has been a long-standing goal of the gene-editing field. Not only could this potentially treat many patients regardless of which mutation they have in a disease-causing gene, but it would also preserve the surrounding DNA sequences, which would increase the likelihood that the newly installed gene is properly regulated, rather than expressed too much, too little, or at the wrong time. In 2021, Liu’s lab reported a key step towards this goal and developed a prime editing approach called twinPE that installed recombinase “landing sites” in the genome, and then used natural recombinase enzymes such as Bxb1 to catalyze the insertion of new DNA into the prime edited target sites. The biotech company Prime Medicine, co-founded by Liu, soon began using this technology, which they called PASSIGE (prime-editing-assisted site-specific integrase gene editing), to develop treatments for genetic diseases. PASSIGE installs edits in only a modest fraction of cells, which is enough to treat some but probably not most genetic diseases that result from the loss of a functioning gene. So Liu’s team, in the new work reported today, set out to boost PASSIGE’s editing efficiency. They found that the recombinase enzyme Bxb1 was the culprit in limiting the efficiency of PASSIGE. They then used a tool previously developed by Liu’s group called PACE (phage-assisted continuous evolution) to rapidly evolve more efficient versions of Bxb1 in the lab. The resulting newly evolved and engineered Bxb1 variant (eeBxb1) improved the eePASSIGE method to integrate an average of 30 percent of gene-sized cargo in mouse and human cells, four times more than the original technique and about 16 times more than another recently published method called PASTE. “The eePASSIGE system provides a promising foundation for studies integrating healthy gene copies at sites of our choosing in cell and animal models of genetic diseases to treat loss-of-function disorders,” Liu said. “We hope this system will prove to be an important step towards realizing the benefits of targeted gene integration for patients.” With this goal in mind, Liu’s team is now working on combining eePASSIGE with delivery systems such as engineered virus-like particles (eVLPs) that may overcome hurdles that have traditionally limited the therapeutic delivery of gene editors in the body. Reference: “Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing” by Smriti Pandey, Xin D. Gao, Nicholas A. Krasnow, Amber McElroy, Y. Allen Tao, Jordyn E. Duby, Benjamin J. Steinbeck, Julia McCreary, Sarah E. Pierce, Jakub Tolar, Torsten B. Meissner, Elliot L. Chaikof, Mark J. Osborn and David R. Liu, 10 June 2024, Nature Biomedical Engineering. DOI: 10.1038/s41551-024-01227-1 This work was supported in part by the National Institutes of Health, the Bill and Melinda Gates Foundation, and the Howard Hughes Medical Institute.

The research found a strong indication that the BTNL9 protein helps cells in maintaining healthy cholesterol levels. The Finding Demonstrates How Vital It Is To Ensure Diversity in Genetic Databases According to a recent study conducted by geneticists at the University of Pittsburgh School of Public Health in collaboration with several other organizations, including the University of Otago and the Samoan health research community, the discovery of a genetic variant that is relatively common among individuals of Polynesian descent but very rare in most other populations is providing clues to the genetic underpinnings of high cholesterol in all people. Jenna Carlson, Ph.D. Credit: Jenna Carlson The unexpected finding underscores the value of ensuring diversity in genetic databases and was recently published in the journal Human Genetics and Genomics Advances. “If we had only been looking in populations with European ancestry, we might have missed this finding entirely,” said lead author Jenna Carlson, Ph.D., assistant professor of human genetics and biostatistics at Pitt Public Health. “It was through the generosity of thousands of Polynesian people that we were able to find this variant, which is a smoking gun that will spark new research into the biology underlying cholesterol.” According to the World Health Organization, high cholesterol is a significant source of disease burden in nations of all economic levels, is a risk factor for heart disease and stroke, and is estimated to cause 2.6 million deaths globally each year. Exploring the Role of BTNL9 in Cholesterol Regulation Carlson and her team built their study to explore a signal that popped up in a large genome-wide survey looking for genes associated with lipids, or fats, in the body. It suggested that a gene variant on chromosome 5 could be associated with cholesterol. The team set out to “fine map” the region using genetic data from 2,851 Samoan adults from the Obesity, Lifestyle, And Genetic Adaptations (OLAGA, which means “life” in Samoan) Study Group who had also provided health information, including lipid panels. To double-check the finding, the team looked for the association in 3,276 other Polynesian people from Samoa, American Samoa, and Aotearoa New Zealand, and the same connection between the variant and cholesterol was seen in them. Identifying the Stop-Gain Variant in Polynesians Using data from the western Polynesian Samoan participants, the team was able to fill in the missing information around the region they were interested in on chromosome 5. This led them to BTNL9 – a gene that directs the production of the BTNL9 protein. Proteins typically signal to cells to perform actions, though scientists still haven’t characterized the precise role of the BTNL9 protein. It turned out that Polynesian people with low levels of HDL “good” cholesterol and high levels of triglycerides had a “stop-gain” variant in BTNL9, which means the gene was being directed to stop doing its protein-production job, a strong hint that the BTNL9 protein is involved in helping cells maintain healthy cholesterol levels. “We don’t know a lot about this variant because it’s not seen in published genome references, which overrepresent European ancestry individuals – it’s virtually nonexistent in European ancestry populations, has a very low frequency in South Asians, and isn’t even particularly common in eastern Polynesian people, such as Māori living in Aotearoa New Zealand,” Carlson said. “But the way it’s linked to lipid panels in Samoan people tells us that this gene is important to cholesterol, something we didn’t know before. By further exploring BTNL9, we might someday discover new ways to help everyone maintain healthy cholesterol levels.” Reference: “A stop-gain variant in BTNL9 is associated with atherogenic lipid profiles” by Jenna C. Carlson, Mohanraj Krishnan, Samantha L. Rosenthal, Emily M. Russell, Jerry Z. Zhang, Nicola L. Hawley, Jaye Moors, Hong Cheng, Nicola Dalbeth, Janak R. de Zoysa, Huti Watson, Muhammad Qasim, Rinki Murphy, Take Naseri, Muagututi’a Sefuiva Reupena, Satupa‘itea Viali, Lisa K. Stamp, John Tuitele, Erin E. Kershaw, Ranjan Deka, and Ryan L. Minster, 12 October 2022, Human Genetics and Genomics Advances. DOI: 10.1016/j.xhgg.2022.100155 The study was funded by the National Institutes of Health (NIH) and the New Zealand Health Research Council.

DVDV1551RTWW78V